CAS Medical Systems, Inc. (NASDAQ:CASM) – Research analysts at Zacks Investment Research lifted their FY2018 earnings per share estimates for CAS Medical Systems in a report issued on Tuesday, May 15th. Zacks Investment Research analyst B. Marckx now expects that the medical technology company will earn ($0.26) per share for the year, up from their prior forecast of ($0.28). Zacks Investment Research also issued estimates for CAS Medical Systems’ FY2019 earnings at ($0.13) EPS and FY2020 earnings at ($0.07) EPS.
CAS Medical Systems (NASDAQ:CASM) last announced its quarterly earnings results on Thursday, May 10th. The medical technology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.01. The firm had revenue of $5.44 million during the quarter, compared to the consensus estimate of $4.85 million.
Separately, ValuEngine raised shares of CAS Medical Systems from a “hold” rating to a “buy” rating in a report on Thursday.
Shares of CAS Medical Systems opened at $1.69 on Friday, MarketBeat reports. The company has a current ratio of 1.54, a quick ratio of 1.38 and a debt-to-equity ratio of -0.34. CAS Medical Systems has a one year low of $1.38 and a one year high of $1.44.
In related news, major shareholder Acuta Capital Fund, Lp acquired 37,520 shares of the company’s stock in a transaction dated Wednesday, June 20th. The stock was bought at an average cost of $1.01 per share, with a total value of $37,895.20. Following the acquisition, the insider now owns 2,903,117 shares of the company’s stock, valued at approximately $2,932,148.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders acquired 232,920 shares of company stock valued at $248,718 and sold 8,000 shares valued at $10,310. 37.60% of the stock is owned by company insiders.
A hedge fund recently raised its stake in CAS Medical Systems stock. Acuta Capital Partners LLC lifted its stake in shares of CAS Medical Systems, Inc. (NASDAQ:CASM) by 1.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,216,998 shares of the medical technology company’s stock after acquiring an additional 56,998 shares during the period. CAS Medical Systems makes up 1.1% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 16th biggest position. Acuta Capital Partners LLC owned about 18.17% of CAS Medical Systems worth $6,573,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.41% of the company’s stock.
About CAS Medical Systems
CAS Medical Systems, Inc, a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories, as well as offers FORE-SIGHT ELITE monitors. Its FORE-SIGHT absolute tissue oximeter provides non-invasive and quantitative measurement of oxygenation for cerebral tissue during surgery or critical care situations.
Receive News & Ratings for CAS Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAS Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.